New York State Teachers Retirement System Sells 2,900 Shares of Repligen Corporation (NASDAQ:RGEN)

New York State Teachers Retirement System decreased its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 5.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 51,032 shares of the biotechnology company's stock after selling 2,900 shares during the quarter. New York State Teachers Retirement System owned 0.09% of Repligen worth $6,493,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV grew its position in Repligen by 14.9% during the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Repligen by 3.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 473,486 shares of the biotechnology company's stock worth $60,843,000 after acquiring an additional 16,421 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Repligen by 60.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,822 shares of the biotechnology company's stock valued at $3,979,000 after buying an additional 11,193 shares during the last quarter. Artemis Investment Management LLP raised its position in shares of Repligen by 110.1% during the first quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock valued at $41,128,000 after buying an additional 169,397 shares during the last quarter. Finally, Bessemer Group Inc. raised its position in shares of Repligen by 1.7% during the first quarter. Bessemer Group Inc. now owns 253,014 shares of the biotechnology company's stock valued at $32,193,000 after buying an additional 4,325 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

RGEN has been the topic of several research analyst reports. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Wall Street Zen downgraded shares of Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Finally, Royal Bank Of Canada reduced their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $172.83.

Repligen Price Performance

RGEN stock traded down $1.21 during trading on Monday, reaching $126.26. 94,096 shares of the company were exchanged, compared to its average volume of 726,931. The company has a 50-day moving average of $126.70 and a two-hundred day moving average of $139.87. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of -281.38, a P/E/G ratio of 3.65 and a beta of 1.11. Repligen Corporation has a twelve month low of $102.97 and a twelve month high of $182.52. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period in the prior year, the company earned $0.28 EPS. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. As a group, equities analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.